These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 18154479)

  • 1. Integrase inhibitors: a new treatment option for patients with human immunodeficiency virus infection.
    Correll T; Klibanov OM
    Pharmacotherapy; 2008 Jan; 28(1):90-101. PubMed ID: 18154479
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integrase inhibitors: a novel class of antiretroviral agents.
    Schafer JJ; Squires KE
    Ann Pharmacother; 2010 Jan; 44(1):145-56. PubMed ID: 20040702
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Next-generation integrase inhibitors : where to after raltegravir?
    Karmon SL; Markowitz M
    Drugs; 2013 Mar; 73(3):213-28. PubMed ID: 23413196
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Raltegravir: the first HIV integrase inhibitor.
    Cocohoba J; Dong BJ
    Clin Ther; 2008 Oct; 30(10):1747-65. PubMed ID: 19014832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Raltegravir: an integrase inhibitor for HIV-1.
    Evering TH; Markowitz M
    Expert Opin Investig Drugs; 2008 Mar; 17(3):413-22. PubMed ID: 18321239
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Raltegravir (MK-0518): an integrase inhibitor for the treatment of HIV-1.
    Evering TH; Markowitz M
    Drugs Today (Barc); 2007 Dec; 43(12):865-77. PubMed ID: 18174972
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Raltegravir (MK-0518): a novel integrase inhibitor for the treatment of HIV infection.
    Anker M; Corales RB
    Expert Opin Investig Drugs; 2008 Jan; 17(1):97-103. PubMed ID: 18095922
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elvitegravir, an oral HIV integrase inhibitor, for the potential treatment of HIV infection.
    Klibanov OM
    Curr Opin Investig Drugs; 2009 Feb; 10(2):190-200. PubMed ID: 19197797
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Update on raltegravir and the development of new integrase strand transfer inhibitors.
    Shamroe CL; Bookstaver PB; Rokas KE; Weissman SB
    South Med J; 2012 Jul; 105(7):370-8. PubMed ID: 22766666
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The use of HIV-1 integrase inhibitors in antiretroviral naive patients.
    Lennox JL
    Curr Opin HIV AIDS; 2012 Sep; 7(5):409-14. PubMed ID: 22789985
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals.
    Markowitz M; Morales-Ramirez JO; Nguyen BY; Kovacs CM; Steigbigel RT; Cooper DA; Liporace R; Schwartz R; Isaacs R; Gilde LR; Wenning L; Zhao J; Teppler H
    J Acquir Immune Defic Syndr; 2006 Dec; 43(5):509-15. PubMed ID: 17133211
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial.
    Grinsztejn B; Nguyen BY; Katlama C; Gatell JM; Lazzarin A; Vittecoq D; Gonzalez CJ; Chen J; Harvey CM; Isaacs RD;
    Lancet; 2007 Apr; 369(9569):1261-1269. PubMed ID: 17434401
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study.
    Molina JM; Lamarca A; Andrade-Villanueva J; Clotet B; Clumeck N; Liu YP; Zhong L; Margot N; Cheng AK; Chuck SL;
    Lancet Infect Dis; 2012 Jan; 12(1):27-35. PubMed ID: 22015077
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MK-0518 and GS-9137: two promising integrase inhibitors in the pipeline.
    O'Neal R
    BETA; 2006; 18(4):13-6. PubMed ID: 17019786
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emerging pharmacology: inhibitors of human immunodeficiency virus integration.
    Hazuda D; Iwamoto M; Wenning L
    Annu Rev Pharmacol Toxicol; 2009; 49():377-94. PubMed ID: 18928385
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HIV integrase inhibitors: a new era in the treatment of HIV.
    Blanco JL; Whitlock G; Milinkovic A; Moyle G
    Expert Opin Pharmacother; 2015 Jun; 16(9):1313-24. PubMed ID: 26001181
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Raltegravir: a new antiretroviral class for salvage therapy.
    Cahn P; Sued O
    Lancet; 2007 Apr; 369(9569):1235-1236. PubMed ID: 17434380
    [No Abstract]   [Full Text] [Related]  

  • 18. [Efficacy of raltegravir: from healthy volunteers to phase III trials].
    Gatell JM
    Enferm Infecc Microbiol Clin; 2008 Nov; 26 Suppl 12():29-33. PubMed ID: 19572423
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase.
    Murray JM; Emery S; Kelleher AD; Law M; Chen J; Hazuda DJ; Nguyen BY; Teppler H; Cooper DA
    AIDS; 2007 Nov; 21(17):2315-21. PubMed ID: 18090280
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel integrase inhibitors for HIV.
    Prada N; Markowitz M
    Expert Opin Investig Drugs; 2010 Sep; 19(9):1087-98. PubMed ID: 20707594
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.